AU725965C - Method of enhancing bioavailability of fexofenadine and its derivatives - Google Patents

Method of enhancing bioavailability of fexofenadine and its derivatives

Info

Publication number
AU725965C
AU725965C AU85050/98A AU8505098A AU725965C AU 725965 C AU725965 C AU 725965C AU 85050/98 A AU85050/98 A AU 85050/98A AU 8505098 A AU8505098 A AU 8505098A AU 725965 C AU725965 C AU 725965C
Authority
AU
Australia
Prior art keywords
peg
glycoprotein
glycoprotein inhibitor
fexofenadine
water soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU85050/98A
Other languages
English (en)
Other versions
AU725965B2 (en
AU8505098A (en
Inventor
Dennis H. Giesing
Gail H. Hurst
Kin-Kai Hwang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of AU8505098A publication Critical patent/AU8505098A/en
Publication of AU725965B2 publication Critical patent/AU725965B2/en
Assigned to AVENTIS PHARMACEUTICALS INC. reassignment AVENTIS PHARMACEUTICALS INC. Amend patent request/document other than specification (104) Assignors: HOECHST MARION ROUSSEL, INC.
Application granted granted Critical
Publication of AU725965C publication Critical patent/AU725965C/en
Assigned to AVENTIS HOLDINGS INC. reassignment AVENTIS HOLDINGS INC. Alteration of Name(s) in Register under S187 Assignors: AVENTIS PHARMACEUTICALS INC.
Assigned to AVENTISUB II INC. reassignment AVENTISUB II INC. Alteration of Name(s) in Register under S187 Assignors: AVENTIS HOLDINGS INC.
Assigned to AVENTISUB LLC reassignment AVENTISUB LLC Request to Amend Deed and Register Assignors: AVENTISUB II INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU85050/98A 1997-08-14 1998-07-21 Method of enhancing bioavailability of fexofenadine and its derivatives Expired AU725965C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91156397A 1997-08-14 1997-08-14
US08/911563 1997-08-14
PCT/US1998/015098 WO1999008690A1 (en) 1997-08-14 1998-07-21 Method of enhancing bioavailability of fexofenadine and its derivatives

Publications (3)

Publication Number Publication Date
AU8505098A AU8505098A (en) 1999-03-08
AU725965B2 AU725965B2 (en) 2000-10-26
AU725965C true AU725965C (en) 2004-04-22

Family

ID=25430473

Family Applications (1)

Application Number Title Priority Date Filing Date
AU85050/98A Expired AU725965C (en) 1997-08-14 1998-07-21 Method of enhancing bioavailability of fexofenadine and its derivatives

Country Status (29)

Country Link
EP (1) EP1003528B1 (enExample)
JP (1) JP4295913B2 (enExample)
KR (1) KR100522985B1 (enExample)
CN (1) CN1143680C (enExample)
AR (1) AR018505A1 (enExample)
AT (1) ATE224721T1 (enExample)
AU (1) AU725965C (enExample)
BR (1) BR9811937A (enExample)
CA (1) CA2301267C (enExample)
CZ (1) CZ293666B6 (enExample)
DE (1) DE69808303T2 (enExample)
DK (1) DK1003528T3 (enExample)
EE (1) EE04263B1 (enExample)
ES (1) ES2179523T3 (enExample)
HU (1) HU226823B1 (enExample)
ID (1) ID24463A (enExample)
IL (1) IL134521A (enExample)
NO (1) NO325148B1 (enExample)
NZ (1) NZ502133A (enExample)
OA (1) OA11287A (enExample)
PL (1) PL191607B1 (enExample)
PT (1) PT1003528E (enExample)
RU (1) RU2197967C2 (enExample)
SK (1) SK283868B6 (enExample)
TR (1) TR200000419T2 (enExample)
TW (1) TWI240633B (enExample)
UA (1) UA64765C2 (enExample)
WO (1) WO1999008690A1 (enExample)
ZA (1) ZA987221B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
EP0998272B1 (en) * 1997-08-26 2003-05-02 Aventis Pharmaceuticals Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
WO2003101437A2 (en) * 2002-05-29 2003-12-11 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
JP2008120684A (ja) * 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
KR101106374B1 (ko) 2009-06-05 2012-01-19 민병욱 고체연료에 의한 가연성 가스 발생 장치
KR101117014B1 (ko) * 2009-09-09 2012-06-14 민병욱 부패성 폐기물의 바이오매스 처리에 의한 폐자원 재활용 방법 및 장치
CN101843616B (zh) * 2010-06-04 2011-07-27 西安万隆制药有限责任公司 一种盐酸非索非那定与微晶纤维素组合物及其制备方法
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
EA201391742A1 (ru) 2011-05-20 2014-04-30 Авентис Фармасьютикалз Инк. Фармацевтическая композиция, включающая фексофенадин
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
RU2553362C1 (ru) * 2014-01-09 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ моделирования состояния ингибирования функциональной активности гликопротеина-р линестренолом в эксперименте
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020980A1 (en) * 1994-02-02 1995-08-10 The Regents Of The University Of California Method for increasing bioavailability of oral pharmaceutical compositions
WO1996040792A1 (en) * 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
NO900427L (no) * 1989-01-31 1990-08-01 Int Pharma Agentur Erosjonsregulert frigjoeringssystem for aktive stoffer og en fremgangsmaate for deres fremstilling.
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020980A1 (en) * 1994-02-02 1995-08-10 The Regents Of The University Of California Method for increasing bioavailability of oral pharmaceutical compositions
WO1996040792A1 (en) * 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides

Also Published As

Publication number Publication date
NO20000706L (no) 2000-04-13
CZ293666B6 (cs) 2004-06-16
EP1003528A1 (en) 2000-05-31
RU2197967C2 (ru) 2003-02-10
ZA987221B (en) 1999-02-15
DE69808303D1 (de) 2002-10-31
SK1842000A3 (en) 2000-08-14
HU226823B1 (hu) 2009-11-30
NZ502133A (en) 2002-03-28
IL134521A0 (en) 2001-04-30
UA64765C2 (uk) 2004-03-15
WO1999008690A1 (en) 1999-02-25
DK1003528T3 (da) 2003-02-03
PL191607B1 (pl) 2006-06-30
CN1267221A (zh) 2000-09-20
HK1025901A1 (en) 2000-12-01
EE200000069A (et) 2000-10-16
CA2301267A1 (en) 1999-02-25
PL338579A1 (en) 2000-11-06
JP4295913B2 (ja) 2009-07-15
ATE224721T1 (de) 2002-10-15
KR100522985B1 (ko) 2005-10-21
CN1143680C (zh) 2004-03-31
SK283868B6 (sk) 2004-03-02
BR9811937A (pt) 2000-09-05
CZ2000522A3 (cs) 2000-09-13
DE69808303T2 (de) 2003-05-22
ID24463A (id) 2000-07-20
EP1003528B1 (en) 2002-09-25
AU725965B2 (en) 2000-10-26
OA11287A (en) 2003-10-22
NO20000706D0 (no) 2000-02-11
AU8505098A (en) 1999-03-08
TR200000419T2 (tr) 2000-09-21
HUP0003189A2 (en) 2001-03-28
EE04263B1 (et) 2004-04-15
KR20010022845A (ko) 2001-03-26
AR018505A1 (es) 2001-11-28
PT1003528E (pt) 2003-02-28
HUP0003189A3 (en) 2001-04-28
JP2001515041A (ja) 2001-09-18
CA2301267C (en) 2004-07-13
NO325148B1 (no) 2008-02-11
TWI240633B (en) 2005-10-01
ES2179523T3 (es) 2003-01-16
IL134521A (en) 2005-07-25

Similar Documents

Publication Publication Date Title
US6451815B1 (en) Method of enhancing bioavailability of fexofenadine and its derivatives
EP1003528B1 (en) Method of enhancing bioavailability of fexofenadine and its derivatives
EP1474172B1 (en) Pharmaceutical compositions for hepatitis c viral protease inhibitors
EP1216025B1 (en) Dispersion formulations containing lipase inhibitors
ZA200307684B (en) Antifungal composition with enhanced bioavailability
US20040229939A1 (en) Tetrahydrocannabinol compositions and methods of manufacture and use thereof
US20150190413A1 (en) Compositions and methods for the treatment of bladder cancer
JP2001515041A5 (enExample)
JP2873595B2 (ja) ピペリジノアルカノール誘導体類用の液体製剤組成物
RU2266736C2 (ru) Способ и композиции для ингибирования артериосклероза
HK1025901B (en) Method of enhancing bioavailability of fexofenadine and its derivatives
MXPA00001515A (en) Method of enhancing bioavailability of fexofenadine and its derivatives
KR100569595B1 (ko) 가용성 심바스타틴의 연질캡슐제 조성물 및 그의제조방법
CA2355271A1 (en) Cyclosporin solution
WO2009056256A1 (en) Use of megestrol acetate having improved solubility for the treatment of cancer cachexia
HK1091130B (en) Pharmaceutical compositions for hepatitis c viral protease inhibitors
HK1091130A1 (en) Pharmaceutical compositions for hepatitis c viral protease inhibitors
WO2009111555A1 (en) Combination treatment for bladder cancer comprisining valrubicin and trospium chloride
HK1129053A (en) Antifungal composition with enhanced bioavailability

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: AVENTIS PHARMACEUTICALS INC.

Free format text: FORMER NAME: HOECHST MARION ROUSSEL, INC.

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20030731

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20030911

MK14 Patent ceased section 143(a) (annual fees not paid) or expired